Antisense oligonucleotide targeting atn1 mrna or pre-mrna
AssigneesNippon Shinyaku Co., Ltd., Niigata University
InventorsTakao KAWANO, Toshiaki ODE, Akie CHIBA, Osamu ONODERA, Taisuke KATO, Sachiko HIROKAWA
Life of this patent
Estimating the term…
Abstract
The present invention provides an antisense oligonucleotide that is formed of 15-22 nucleotides and that is complementary to a nucleic acid including at least 15 consecutive bases in a specific target region of a base sequence of SEQ ID NO: 471, or a pharmaceutically acceptable salt thereof, or hydrates of those.
Claims35
An antisense oligonucleotide consisting of 15 to 22 nucleotides complementary to a nucleic acid comprising at least 15 consecutive bases in a region selected from the group consisting of positions 1 to 84, 142 to 168, 197 to 224, 286 to 317, 324 to 370, 391 to 434, 519 to 540, 623 to 643, 690 to 780, 824 to 855, 860 to 897, 948 to 987, 1044 to 1072, 1125 to 1174, 1181 to 1213, 1228 to 1255, 1265 to 1327, 1334 to 1356, 1416 to 1440, 1447 to 1631, 1638 to 1667, 1675 to 1705, 1748 to 1823, 1838 to 1861, 1870 to 1913, 1920 to 1941, 2000 to 2040, 2047 to 2075, 2086 to 2120, 2129 to 2187, 2194 to 2415, 2451 to 2497, 2592 to 2759, 2766 to 2870, 2928 to 2948, 2955 to 2989, 3021 to 3086, 3133 to 3209, 3217 to 3284, 3295 to 3350, 3384 to 3436, 3562 to 3771, 3858 to 3905, 3931 to 4039, 4067 to 4134, 4170 to 4232, 4241 to 4283, and 4286 to 4355 of a base sequence of SEQ ID NO:
- 471, or a pharmaceutically acceptable salt thereof, or a hydrate thereof.
An antisense oligonucleotide consisting of 15 to 22 nucleotides complementary to a nucleic acid comprising at least 15 consecutive bases in a target region selected from the group consisting of positions 468 to 487, 474 to 493, 583 to 602, 586 to 605, 619 to 638, 770 to 789, 774 to 793, 775 to 794, 778 to 797, 804 to 823, 851 to 870, 1160 to 1179, 1162 to 1181, 1170 to 1189, 1173 to 1192, 1205 to 1224, 1210 to 1229, 1216 to 1235, 1217 to 1236, 1219 to 1238, 1385 to 1404, 1441 to 1460, 1818 to 1837, 1902 to 1921, 1905 to 1924, 1908 to 1927, 1914 to 1933, 1931 to 1950, 2117 to 2136, 2749 to 2768, 3100 to 3119, and 4125 to 4144 of a base sequence of SEQ ID NO:
- 471, or a pharmaceutically acceptable salt thereof, or a hydrate thereof.
Dependencies are inferred from the claim text.